Welcome to our dedicated page for Bicara Therapeutics SEC filings (Ticker: BCAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bicara Therapeutics Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing bifunctional therapies for solid tumors. Forms 8-K record financial results, business highlights, ficerafusp alfa clinical updates, material definitive agreements and other events, including common stock and pre-funded warrant financing.
The company’s proxy materials cover annual meeting proposals, board-class elections, auditor ratification and governance matters for an emerging growth company. The filings also describe capital-structure actions and formal exhibits tied to press releases, underwriting agreements and shareholder voting matters.
BCAX notice of proposed sale: 5,500 shares of Common Stock are listed for sale in a Form 144 tied to an exercise of stock options and dated 05/26/2026. The filing also lists recent sales by David Raben on 03/03/2026, 03/04/2026, 03/25/2026, and 04/27/2026 with quantities shown. Cash settlement is indicated.
Bicara Therapeutics reported three-year follow-up data from its Phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line HPV-negative recurrent/metastatic head and neck squamous cell carcinoma. At the pivotal 1500mg weekly dose, the combination showed an estimated 31% overall survival at three years, approximately doubling survival versus a retrospective standard-of-care pembrolizumab analysis.
Across 750mg weekly, 1500mg weekly and 2000mg every-other-week cohorts, confirmed response rates ranged from 48–57%, with complete response rates of 13%, 25% and 30% as of March 31, 2026. Deep responses of at least 80% tumor shrinkage were common at higher doses and were associated with longer duration of response, progression-free survival and overall survival. Bicara highlighted biomarker data supporting TGF-β inhibition as the driver of these deep, durable responses and noted that the pivotal FORTIFI-HN01 Phase 2/3 study and an alternate dosing study are ongoing or planned.
BCAX notice of proposed sale: a holder filed a Form 144 reporting an intended sale of 9,200 shares of Common Stock on 05/21/2026 related to an exercise of stock options and settled in cash. The filing also lists multiple prior dispositions in March–April 2026.
Bicara Therapeutics Inc. Chief Executive Officer Claire Mazumdar reported a mix of stock sales and option exercises in common stock. She sold a total of 15,000 shares in open-market transactions at weighted average prices of $20.3481 and $19.9619 per share under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. She also exercised stock options to acquire 15,000 shares of common stock at an exercise price of $3.7898 per share. Following these transactions, she directly holds 377,152 shares of common stock and retains stock options covering 146,107 shares.
Bicara Therapeutics President and COO Ryan Cohlhepp reported routine transactions in company stock. On May 15, 2026, he sold a total of 12,500 shares of common stock in open-market trades at a weighted average price of $20.2919 per share under a pre-arranged Rule 10b5-1 trading plan. On the same date, he exercised stock options to acquire 8,000 shares of common stock at an exercise price of $3.7898 per share. Following these transactions, he held 191,641 shares of common stock directly and 101,334 stock options for additional shares.
BCAX insider files a Form 144 proposing to sell 15,000 shares of Common Stock. The filing lists the proposed sale as an exercise of stock options with a transaction date of 05/18/2026. The notice also discloses multiple open-market dispositions by Claire Mazumdar during March–April 2026, including sales on 03/09/2026 (36,766 shares) and 04/20/2026 (15,000 shares).
Bicara Therapeutics ownership update: Vestal Point Capital, LP and Ryan Wilder report beneficial ownership of 5,425,000 shares of Bicara Therapeutics common stock. The reporting persons state this equals 8.3% of 65,467,187 shares outstanding as of March 24, 2026, per the company’s Form 10-K. The filing identifies the shares as held by the Vestal Point Fund and Account and attributes shared voting and dispositive power of 5,425,000 to the Investment Manager and to Mr. Wilder in his managerial capacities.
BCAX insider filings report multiple cash sales of Common stock. The filing lists four transactions dated 02/25/2026, 03/03/2026, 03/16/2026 and 04/15/2026 by the reporting person, with per‑trade share counts and gross proceeds disclosed.
Janus Henderson Group plc reported beneficial ownership of 3,339,218 shares of Bicara Therapeutics Inc. (Common Stock), representing 5.1% of the class as of 03/31/2026 in a Schedule 13G filing. The filing states these holdings arise from discretionary management of client portfolios and that the Asset Managers disclaim rights to dividends or sale proceeds.
Bicara Therapeutics Schedule 13G/A shows Deep Track-related reporting persons beneficially own 4,062,500 shares of common stock, representing 6.21% of the class. The filing states 65,467,187 shares outstanding as of March 24, 2026 (issuer 10-K). The ownership is reported as shared voting and dispositive power and is reported by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin.